Want to save up to 80% on your medications? Signup below to be notified if we open a Canadian Online Pharmacy.
Thanks for Visiting Canada Drugs Direct.
Currently we are preparing to serve our canadian visitors, we will update you when we are ready!
Please save your reference number: for further communication.
Top brand choice
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
SPRYCEL (dasatinib) is a prescription medicine used to treat adults who have:
chronic myeloid leukemia (CML) who are no longer benefitting from, or cannot tolerate, prior treatment including GLEEVECr (imatinib mesylate)
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are no longer benefitting from, or cannot tolerate, prior treatment